PIPELINE

LEAD
PROGRAMS

AU409 — Liver Cancer & CRCLM

Status: Phase 1 Clinical Trial

AI-discovered, first-in-class oral transcription modulator demonstrating encouraging clinical activity in advanced hepatocellular carcinoma (HCC), including a durable complete response* by mRECIST. Development is also targeting colorectal cancer liver metastases (CRCLM).

*Partial response by RECIST 1.1.

SEE SCIENCE BEHIND AU409 >>

AU018 — Heart-Safe Chemotherapy

Status: Preclinical / IND-Enabling Studies

AI-discovered therapeutic program developed and validated in collaboration with SCT, designed to improve the cardiac safety of anthracycline chemotherapy while preserving anticancer efficacy.

100+

Diseases

Our pipeline represents only a fraction of the opportunities identified through Auransa's biology-first AI platform. We have analyzed more than 100 traditionally classified diseases, revealing biologically distinct subtypes and opportunities to develop targeted therapeutics beyond conventional disease classifications.